CMS Remedy For 340B ‘Double Dipping’ Relies On States, Medicaid Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma manufacturers will likely be disappointed that CMS decided against imposing a drug claim reporting format for Medicaid plans to help ensure drugs getting 340B discounts are not also subject to Medicaid rebates.